Human epidermal growth factor receptor 2 overexpression is associated with high-grade tumors in upper tract urothelial carcinoma

Table 1 Clinicopathologic characteristics of upper tract urothelial carcinoma patients and human epidermal growth factor receptor 2 groups

Variable	Category	Total	HER2-negative	HER2-positive	P value
Age		66 (32-88)	68 (32-84)	65 (35-88)
Gender					0.736
	Male	93	51	42
	Female	52	27	25
Location					0.156
	Renal pelvis	78	44	34
	Ureter	64	34	30
	Both	3	0	3
pT stage					0.426
	≤ T1	36	16	20
	T2	31	18	13
	≥ T3	78	44	34
Grade					0.003
	Low	20	17	3
	High	125	61	64
Ki-67					0.479
	Low	30	14	16
	High	115	62	53
pN stage					0.646
	Yes	8	4	4
	No	137	74	63
Lymphovascular invasion					0.135
	pN1	39	17	22
	pN0	106	61	45
Laterality					0.639
	Left	68	30	38
	Right	77	31	46
Molecular subtypes					0.788
	Luminal	102	53	49
	Basal	22	14	8
	Double-positive	10	5	5
	Double-negative	11	6	5

HER2: Human epidermal growth factor receptor 2.

Table 2 Univariate and multivariable logistic regression analysis for the clinicopathologic characteristics on human epidermal growth factor receptor 2 expression

Variable	Univariate HR (95%CI)	P value	Multivariate HR (95%CI)	P value
Age (per year)	1.01 (0.98-1.04)	0.62
Gender (female vs male)	1.12 (0.58-2.17)	0.74
Tumor location (ureter vs renal pelvis)	1.13 (0.60-2.13)	0.71
pT stage (T2 vs ≤ T1)	0.72 (0.30-1.74)	0.47
pT stage (≥ T3 vs ≤ T1)	0.77 (0.36-1.65)	0.5
Grade (high vs low)	3.56 (1.30-9.75)	0.013a	3.42 (1.22-9.60)	0.019a
Ki-67 (high vs low)	0.76 (0.34-1.70)	0.5
Lymph node metastasis (yes vs no)	1.17 (0.30-4.58)	0.82
Lymphovascular invasion (yes vs no)	1.56 (0.76-3.20)	0.23
Laterality (right vs left)	1.17 (0.60-2.28)	0.647
Molecular subtype (basal vs luminal)	0.62 (0.24-1.60)	0.32
Molecular subtype (double-positive vs luminal)	1.08 (0.30-3.94)	0.9
Molecular subtype (double-negative vs luminal)	0.90 (0.26-3.14)	0.87

^aP < 0.05.

HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio.

Table 3 The information of patients with intravesical recurrence after radical nephroureterectomy

Variable	n (%)
All	14
Gender
Male	7 (50)
Female	7 (50)
Grade
Low	4 (29)
High	10 (71)
Tumor location
Ureter	8 (57)
Renal pelvis	6 (43)
HER2
Negative	9 (64)
Positive	5 (36)
Stage
≤ T1	4 (29)
T2	1 (7)
≥ T3	9 (64)
Molecular subtype
Luminal	10 (71)
Basal	4 (29)

HER2: Human epidermal growth factor receptor 2.